- Home
- NTLA vs HBT Comparison
NTLA vs HBT Comparison
Compare NTLA & HBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- HBT
- Stock Information
- Founded
- NTLA 2014
- HBT 1920
- Country
- NTLA United States
- HBT United States
- Employees
- NTLA N/A
- HBT N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- HBT Major Banks
- Sector
- NTLA Health Care
- HBT Finance
- Exchange
- NTLA Nasdaq
- HBT Nasdaq
- Market Cap
- NTLA 794.5M
- HBT 706.0M
- IPO Year
- NTLA 2016
- HBT 2019
- Fundamental
- Price
- NTLA $9.20
- HBT $23.63
- Analyst Decision
- NTLA Buy
- HBT Hold
- Analyst Count
- NTLA 20
- HBT 5
- Target Price
- NTLA $36.60
- HBT $25.25
- AVG Volume (30 Days)
- NTLA 6.1M
- HBT 27.0K
- Earning Date
- NTLA 08-07-2025
- HBT 07-21-2025
- Dividend Yield
- NTLA N/A
- HBT 3.57%
- EPS Growth
- NTLA N/A
- HBT 6.07
- EPS
- NTLA N/A
- HBT 2.38
- Revenue
- NTLA $45,569,000.00
- HBT $227,041,000.00
- Revenue This Year
- NTLA N/A
- HBT $8.82
- Revenue Next Year
- NTLA N/A
- HBT $2.74
- P/E Ratio
- NTLA N/A
- HBT $9.93
- Revenue Growth
- NTLA N/A
- HBT 1.69
- 52 Week Low
- NTLA $5.90
- HBT $18.62
- 52 Week High
- NTLA $28.18
- HBT $26.25
- Technical
- Relative Strength Index (RSI)
- NTLA 57.28
- HBT 49.09
- Support Level
- NTLA $8.00
- HBT $23.19
- Resistance Level
- NTLA $10.52
- HBT $24.64
- Average True Range (ATR)
- NTLA 0.67
- HBT 0.59
- MACD
- NTLA 0.15
- HBT -0.06
- Stochastic Oscillator
- NTLA 63.35
- HBT 37.31
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.